Telaprevir

Janessa Smith, Pharm.D. BCPS, Paul A. Pham, Pharm.D.

INDICATIONS

FDA

In combination with peg-interferon and ribavirin, telaprevir indicated for the treatment of HCV (genotype1) patients with compensated liver disease, including cirrhosis, who are treatment-naïve OR who have been previously treated with interferon-based regimen, but had no response, partial response, or relapsed (no longer available in U.S.)

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: February 9, 2018